3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase NA
1
Phase 2
1
Status
Completed
11
Unknown
4
Recruiting
2
Active not recruiting
2
Terminated
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
129
Carcinoma, Non-Small-Cell Lung
101
Prostatic Neoplasms
62
Colorectal Neoplasms
49
Nasopharyngeal Carcinoma
45
Neoplasms
44
Multiple Myeloma
42
Stomach Neoplasms
35
Neoplasm Metastasis
32
Leukemia, Myeloid, Acute
32
Ovarian Neoplasms
31
Lung Neoplasms
31
Carcinoma, Hepatocellular
29
Squamous Cell Carcinoma of Head and Neck
27
Rectal Neoplasms
27
Pancreatic Neoplasms
26
Triple Negative Breast Neoplasms
25
Recurrence
25
Small Cell Lung Carcinoma
21
Brain Neoplasms
21
Esophageal Neoplasms
20
Colonic Neoplasms
20
Uterine Cervical Neoplasms
19
Lymphoma, Large B-Cell, Diffuse
17
Head and Neck Neoplasms
17
Urinary Bladder Neoplasms
16
Leukemia, Lymphocytic, Chronic, B-Cell
16
Esophageal Squamous Cell Carcinoma
16
Carcinoma, Renal Cell
16
Myasthenia Gravis
15
Interventions
exemestane
2
Letrozole
2
ribociclib
1
elacestrant
1
Tamoxifen
1
Leuprolide
1
Goserelin
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Recruiting
×
Breast Neoplasms, Male
×
Clear all
NCT05827081
2026-06-03
Adjuvant WIDER
Novartis
Phase 3
Recruiting
1,400 enrolled
NCT06492616
2026-05-27
ELEGANT
Stemline Therapeutics, Inc.
Phase 3
Recruiting
4,220 enrolled